In AD-converters who are initially cognitively unimpaired, we find that higher plasma GFAP levels are observed as early as 10-years prior to the onset of cognitive impairment due to incident AD compared to those who remain cognitively unimpaired (i.e. in CU). This evidence concerns the gene GFAP and Cognitive impairment.